EXEL Exelixis, Inc.
$65.35▲ +0.37%
Healthcare
Other
After hours
$65.60▲ +0.38%
Oct 27, 5:06 PM ET
Volume 1.43M
Avg Volume (10D) 2.18M
Key Metrics & Fundamentals
Market Cap
$16.19B
P/E Ratio
20.6
Div Yield
0.00%
52W Range
36.00 - 65.59
% vs 50 MA
11.57%
% vs 200 MA
29.23%
RSI-14
73.0
MACD Histogram
+0.3600
Beta (1Y vs SPY)
0.60
Free Cash Flow
$298.43M
Gross Rev
$628.69M
Gross Profit
$608.03M
EBITDA
$255.40M
COGS
$20.66M
Operating Exp
$359.62M
Operating Income
$248.41M
EBIT
$248.41M
Pretax Income
$262.68M
Net Income
$212.05M
EPS (Diluted)
0.82
Price & Volume History
Loading chart…
Recent News
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks · Oct 27, 2026 9:00 AM ET
Bristol Myers Squibb's Cancer Breakthrough Could Have Implications Beyond Its Own Stock
MarketBeat · Oct 26, 2026 1:50 PM ET
Forget the FDA Delay: 3 Reasons Exelixis Is Still a Buy
Motley Fool · Oct 24, 2026 7:20 PM ET
BeOne Stock Tests Buy Zone With Visions Of 177% Earnings Growth. Watch This Clue.
Investor's Business Daily · Oct 23, 2026 1:50 PM ET
Exelixis Rises with Earnings on Tap
FX Empire · Oct 23, 2026 8:23 AM ET
Exelixis (EXEL) Stock May Be A Bargain Despite Its 223% Run
Simply Wall St. · Oct 23, 2026 5:12 AM ET
Exelixis (EXEL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Zacks · Oct 22, 2026 9:00 AM ET
2 Under-the-Radar Stocks to Buy and Hold
Motley Fool · Oct 16, 2026 10:28 AM ET
Exelixis to Release Third Quarter 2026 Financial Results on Thursday, October 29, 2026
Business Wire · Oct 15, 2026 4:05 PM ET
Why Exelixis (EXEL) is Poised to Beat Earnings Estimates Again
Zacks · Oct 15, 2026 11:10 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See EXEL's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.